OCT-guided stent optimization to shorten dual antiplatelet therapy for stable angina
Optical Coherence Tomography for Stent Optimization and Its Impact on Short-Duration Dual Antiplatelet Therapy: A Single-Center, Prospective, Exploratory Study
It will test whether using OCT to optimize stent placement lets people with stable angina who get PCI safely use a shorter course of dual antiplatelet therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Korea University Guro Hospital Academic / other |
| Locations | 1 site (Seoul, Gurodong-ro, Guro-gu) |
| Trial ID | NCT07198529 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-center, open-label pilot registry enrolling patients with stable angina who undergo PCI with a cobalt-chromium everolimus-eluting stent. All participants receive intravascular OCT imaging to guide stent optimization, with DAPT duration determined according to predefined OCT-based criteria and clinical factors. The study tracks ischemic events (including stent thrombosis) and bleeding outcomes during follow-up to determine safety and feasibility of a shortened DAPT strategy. Patients with acute coronary syndromes, technical barriers to OCT, or contraindications to antiplatelet therapy are excluded.
Who should consider this trial
Good fit: Ideal candidates are adults (≥19 years) with stable angina undergoing PCI with a CoCr-everolimus drug-eluting stent who can tolerate OCT and provide informed consent.
Not a fit: Patients with acute coronary syndrome, lesions that prevent OCT or device delivery, contraindications to antiplatelet drugs, or prior stents in the target lesion are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could allow some patients to stop dual antiplatelet therapy sooner, lowering their risk of bleeding without raising stent-related complications.
How similar studies have performed: Prior imaging studies and registry data have shown that OCT-guided optimization can improve stent results and suggested OCT criteria for safe implantation, but few clinical studies have directly tested OCT-guided shortening of DAPT.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who undergo PCI using a cobalt-chromium everolimus-eluting stent (CoCr-EES) * Diagnosis of stable angina * Ability and willingness to provide written informed consent approved by the Institutional Review Board (IRB), and to comply with the study protocol and clinical follow-up schedule * Age ≥ 19 years Exclusion Criteria: * Patients diagnosed with acute coronary syndrome (ACS), including unstable angina or acute myocardial infarction * Contraindications to antiplatelet therapy or OCT imaging * Presence of lesions with severe stenosis, heavy calcification, or marked vessel tortuosity that prevent passage of a guidewire or catheter * Patients with previously implanted coronary stents in the target lesion
Where this trial is running
Seoul, Gurodong-ro, Guro-gu
- Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital — Seoul, Gurodong-ro, Guro-gu, South Korea (Recruiting)
Study contacts
- Study coordinator: Soohyung Park, MD, PhD
- Email: shp503@naver.com
- Phone: +82-10-3105-3710
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.